New York Attorney General Eric Schneiderman's suit against Actavis may have far-reaching implications for other drugmakers.» Read More
The Bill & Melinda Gates Foundation pledged $50 million to support emergency efforts to contain West Africa's Ebola epidemic.
William Ackman criticized Allergan's board of directors, urging them to "wake up" and at least listen to potential purchaser Valeant Pharmaceuticals.
Ilan Ganot left his banking job to form a company to develop drugs to treat his 4-year-old son, who has Duchenne muscular dystrophy.
Ilan Ganot, Solid Ventures, discusses the company's ongoing efforts to develop treatments for Duchenne muscular dystrophy through gene therapy.
CNBC's Meg Tirrell has the story of one dad who quit his job and founded a biotech company in hopes of bringing therapies to market for rare diseases.
AbbVie and Teva were sued by the FTC for allegedly illegally preventing generic production of AndroGel, used by men with low testosterone.
Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.
Three biotech stocks have plenty of potential, John Schroer of Allianz Global Investors says.
U.S. regulators granted accelerated approval to Merck's Keytruda drug, a new type of melanoma treatment for patients with advanced melanoma.
Johnson & Johnson executive Joaquin Duato said the company wants to help save lives by fast tracking its Ebola vaccine.
It was not immediately clear why the talks stalled, but this comes as U.S. companies considering tax inversions come under intense pressure.
Another American missionary doctor has tested positive for Ebola, NBC News reports.
Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.
The potential for Pfizer to take over AstraZeneca has sent its prey’s share price soaring and caused political ructions on both sides of the Atlantic.
Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
Walgreen pharmacies are back online after earlier reporting that many stores couldn't fill prescriptions due to a database failure, Dow Jones said.
50 Cent nominated rival Floyd Mayweather to an Ice Bucket Challenge that didn't involve a bucket of ice water or the ALS Foundation.
Dr. Kent Brantly's release came two days after a second U.S. missionary, Nancy Writebol, was quietly allowed to leave Emory University Hospital.
The FBI has warned that health care industry companies are being targeted by hackers.
Despite the fact that more than a third of U.S. adults are obese, it's been an uphill battle for developers of obesity treatments.
Get the best of CNBC in your inbox